Quarterly ResultAug 6, 2026, 05:15 PM
Sanuwave Q2 Revenue $9.7M, Net Loss $0.7M; Withdraws Guidance
AI Summary
SANUWAVE Health, Inc. announced its Q2 2026 financial results, reporting a 3% decrease in revenue to $9.7 million and a net loss of $0.7 million, a significant decline from net income in the prior year. The company also reported a GAAP operating loss and a substantial drop in Adjusted EBITDA. Citing challenging market conditions and uncertainty around Medicare reimbursement developments, SANUWAVE withdrew its fiscal year 2026 guidance and plans to vigorously contest the proposed CMS rule for 2027 97610 reimbursement.
Key Highlights
- Q2 2026 revenue decreased 3% to $9.7 million from $10.1 million in Q2 2025.
- Reported a net loss of $0.7 million in Q2 2026, compared to net income of $0.6 million in Q2 2025.
- GAAP Operating Loss was $0.3 million for Q2 2026, down from $1.4 million operating income in Q2 2025.
- Adjusted EBITDA fell to $1.2 million in Q2 2026 from $3.2 million in Q2 2025.
- Ultramist applicator revenue increased 13% to $7.3 million in Q2 2026.
- Withdrew previously issued fiscal year 2026 guidance due to market conditions and Medicare reimbursement developments.
- Company will actively comment on the proposed CMS rule for 2027 97610 reimbursement.
Price Impact
More from SNWV